Spotlight on Internal Medicine

Culley C. Carson,  MD, FACS, FRCS(hon)
Credits: 1.0 CME / MOC
Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment
Culley C. Carson, MD, FACS, FRCS(hon)
Vindico Medical Education

Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

Culley C. Carson,  MD, FACS, FRCS(hon)
1.0 CME / MOC
Vindico Medical Education
Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Roy S. Herbst, MD, PhD
0.75 CME / MOC
RMEI Medical Education, LLC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Leonard H. Calabrese, DO
1.0 CME
Vindico Medical Education
Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?

Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: October 20, 2021
Expires: October 19, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
  • Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
  • Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.

Activity Description

In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines.

Agenda

Introduction and Immunopathogenesis of COVID-19 – Leonard H. Calabrese, DO
Assessing Risk for Disease Progression – Cassandra Calabrese, DO
Managing Patients With Severe COVID-19 Infection: What Do We Know? – Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentations – Ivan O. Rosas, MD

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Ownership Interest: Johnson & Johnson


Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


Ivan O. Rosas, MD
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX

Disclosure:
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: October 20, 2021
Expires: October 19, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
  • Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
  • Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.

Activity Description

In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines.

Agenda

Introduction and Immunopathogenesis of COVID-19 – Leonard H. Calabrese, DO
Assessing Risk for Disease Progression – Cassandra Calabrese, DO
Managing Patients With Severe COVID-19 Infection: What Do We Know? – Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentations – Ivan O. Rosas, MD

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Ownership Interest: Johnson & Johnson


Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


Ivan O. Rosas, MD
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX

Disclosure:
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Maria T. Abreu, MD
1.5 CME
Global Education Group
Inflammatory Bowel Disease (IBD) eHealth Source™ Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up To Date? A Focus on Clinical Evidence and Guideline Recommendations

Inflammatory Bowel Disease (IBD) eHealth Source™ Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up To Date? A Focus on Clinical Evidence and Guideline Recommendations

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: October 15, 2021
Expires: October 15, 2022
90 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
  • Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
  • Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
  • Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy

Activity Description

This multimedia IBD eHealth Source™ will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals.

Statement of Educational Need

The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate-to-severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.

Reference

  1. Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.

Faculty

Maria T. Abreu, MD
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
Miami, Florida


Jean-Frédéric Colombel, MD
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Maria T. Abreu, MD
Consultant/Independent Contractor: AbbVie Inc., Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences, Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research Support: Pfizer Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Honoraria (general): AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus Biosciences; Honoraria (teaching, lecturing, or speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda Pharmaceuticals U.S.A., Inc., UCB S.A.

Jean-Frédéric Colombel, MD
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals, Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group; Grant/Research Support: AbbVie Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock Shareholder: Intestinal Biotech Development; Other/Royalty (lectures): AbbVie Inc., Amgen Inc., Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals U.S.A., Inc.

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: October 15, 2021
Expires: October 15, 2022
90 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
  • Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
  • Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
  • Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy

Activity Description

This multimedia IBD eHealth Source™ will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals.

Statement of Educational Need

The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate-to-severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.

Reference

  1. Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.

Faculty

Maria T. Abreu, MD
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
Miami, Florida


Jean-Frédéric Colombel, MD
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Maria T. Abreu, MD
Consultant/Independent Contractor: AbbVie Inc., Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences, Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research Support: Pfizer Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Honoraria (general): AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus Biosciences; Honoraria (teaching, lecturing, or speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda Pharmaceuticals U.S.A., Inc., UCB S.A.

Jean-Frédéric Colombel, MD
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals, Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group; Grant/Research Support: AbbVie Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock Shareholder: Intestinal Biotech Development; Other/Royalty (lectures): AbbVie Inc., Amgen Inc., Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals U.S.A., Inc.

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Michael G. Ison, MD, MS
0.25 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Start

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Ikuo Hirano, MD
1.0 CME
Integrity Continuing Education, Inc.
Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 29, 2022
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants

Learning Objectives

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE

Activity Description

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps and patient case scenarios will illustrate the utility of these agents in clinical practice.

Statement of Educational Need

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life, and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

Program Chair

Ikuo Hirano, MD
Director, Esophageal Center at
Northwestern University, Feinberg School of Medicine
Professor of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Faculty

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia


Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ikuo Hirano, MD (Program Chair)
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire/Takeda

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologies
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC, reported that they or their spouse/life partner, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021, through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 29, 2022
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants

Learning Objectives

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE

Activity Description

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps and patient case scenarios will illustrate the utility of these agents in clinical practice.

Statement of Educational Need

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life, and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

Program Chair

Ikuo Hirano, MD
Director, Esophageal Center at
Northwestern University, Feinberg School of Medicine
Professor of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Faculty

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia


Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ikuo Hirano, MD (Program Chair)
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire/Takeda

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologies
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC, reported that they or their spouse/life partner, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021, through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Bart Duell, MD
1.0 CME / MOC / CNE
American Heart Association
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

Start

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Paul G. Auwaerter, MD, MBA, FIDSA
1.0 CME / CNE / CPE
Postgraduate Institute for Medicine
COVID-19: Keeping Up With a Moving Target – Treatment Updates for Hospitalists

COVID-19: Keeping Up With a Moving Target – Treatment Updates for Hospitalists

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: August 27, 2021
Expires: August 26, 2022
60 minutes to complete

Accredited By

Target Audience

Providers including hospital clinicians, intensivists, and others treating patients with COVID-19 in the hospital setting

Learning Objectives

  • Appraise the efficacy, safety, and indications for treatments for patients with COVID-19 requiring hospitalization.
  • Evaluate management strategies for outpatients with mild to moderate COVID-19.
  • Explain mechanisms of action of monoclonal antibodies (mAbs) and other current and in-development treatments for COVID-19.
  • Describe best practices for managing patients with COVID-19 with mAbs and other agents.

Activity Description

Drs. Paul Long and Paul G. Auwaerter discuss the latest news on treating COVID-19 patients in and out of the hospital.

Topics:

  • Test your knowledge with patient cases
  • Efficacy and safety of treatment options
  • The latest treatment guidelines and recommendations

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland


Paul Long, MD
Assistant Professor of Medicine
General Internal Medicine
Boston University School of Medicine
Boston, Massachusetts

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty/Presenter Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA

Verily (Scientific consulting)
EMD Serono (Scientific consulting)
JNJ (Equity holding)
Humanigen (DSMB)

Paul Long, MD
None

Planners and Managers
The PIM planners and managers have nothing to disclose.
The DKBmed planners and managers have nothing to disclose.
The IJHN Nurse Planner has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Accreditation Statement
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement
This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity until August 27, 2022.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Faculty have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including COVID-19 convalescent plasma, monoclonal antibody treatments, tocilizumab, and dexamethasone.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: August 27, 2021
Expires: August 26, 2022
60 minutes to complete

Accredited By

Target Audience

Providers including hospital clinicians, intensivists, and others treating patients with COVID-19 in the hospital setting

Learning Objectives

  • Appraise the efficacy, safety, and indications for treatments for patients with COVID-19 requiring hospitalization.
  • Evaluate management strategies for outpatients with mild to moderate COVID-19.
  • Explain mechanisms of action of monoclonal antibodies (mAbs) and other current and in-development treatments for COVID-19.
  • Describe best practices for managing patients with COVID-19 with mAbs and other agents.

Activity Description

Drs. Paul Long and Paul G. Auwaerter discuss the latest news on treating COVID-19 patients in and out of the hospital.

Topics:

  • Test your knowledge with patient cases
  • Efficacy and safety of treatment options
  • The latest treatment guidelines and recommendations

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland


Paul Long, MD
Assistant Professor of Medicine
General Internal Medicine
Boston University School of Medicine
Boston, Massachusetts

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty/Presenter Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA

Verily (Scientific consulting)
EMD Serono (Scientific consulting)
JNJ (Equity holding)
Humanigen (DSMB)

Paul Long, MD
None

Planners and Managers
The PIM planners and managers have nothing to disclose.
The DKBmed planners and managers have nothing to disclose.
The IJHN Nurse Planner has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Accreditation Statement
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement
This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity until August 27, 2022.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Faculty have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including COVID-19 convalescent plasma, monoclonal antibody treatments, tocilizumab, and dexamethasone.

Patrick A. Flume, MD
0.50 CME / MOC
RMEI Medical Education, LLC
Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.75 CME / CNE / CPE
Postgraduate Institute for Medicine
Words Matter – Terms to Use and Avoid When Talking About Addiction

Words Matter – Terms to Use and Avoid When Talking About Addiction

Start

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2023
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2023
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Pages